Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Staph Infection Process Leading to B Cell Suicide Described for First Time

05.05.2003


Enhances Potential for Future Development of B-Cell Based Therapy for Lupus



Researchers at the University of California, San Diego—supported by the Alliance for Lupus Research and the National Institutes of Health—have for the first time described a method that Staphylococcus aureus (staph) infection uses to inactivate the body’s immune system. A protein produced by the staph bacteria causes previously healthy B cells—a specialized cell of the immune system—to commit suicide, a process called apoptosis. The research will be published in the May 5 issue of the Journal of Experimental Medicine and at http://www.jem.org/pap.shtml on April 28.

In the new study, the researchers found that SpA, a staph protein, functions as a B cell toxin in mice. The protein attaches to a receptor on B cells, eventually causing the B cells to turn on themselves in a suicide process.


Researchers believe that B cells play a major role in tissue damage that occurs in lupus. “By the targeted elimination of disease-causing B cells, properly dosed injections of SpA may have the potential to control the over-activity of the immune system that causes damage in autoimmune diseases like lupus and in certain cancers,” said Gregg Silverman, M.D., UCSD professor of medicine and senior author of the paper.

“The significance of Dr. Silverman’s research is that the discovery that injections of SpA limit the activity of B cells in animals allows us to proceed to the next step, to test the protein’s usefulness in people,” said John H. Klippel, MD, scientific director of the Alliance for Lupus Research, which funded this study. “If results hold true for people, SpA may eventually prove to be an effective treatment for lupus.”

In addition to Silverman, the study was conducted by the paper’s co-author Carl S. Goodyear, Ph.D., a UCSD postdoctoral researcher.

The study was funded by the National Institutes of Health and the Alliance for Lupus Research. The ALR was founded by Robert Wood Johnson IV, of the Johnson & Johnson healthcare family and owner of the NFL’s New York Jets, with the Arthritis Foundation to raise the profile and scope of lupus research. Since its inception in 1999, the Alliance has committed more than $24 million to research, and has made remarkable gains toward unlocking the mysteries of this disease. ALR directs 100 percent of funds raised to peer-reviewed research and scientific programs. It recently received the highest rating (four stars) from Charity Navigator, an independent resource that evaluates the effectiveness and financial health of more than 2,300 charities.

For more information on our press releases, contact:
Linda De Vito
The Graubard Group
(212) 966-9000
ldevito@graubardgroup.com

Linda De Vito | Alliance for Lupus Research
Further information:
http://www.lupusresearch.org
http://www.lupusresearch.org/press_may1.html
http://www.jem.org/pap.shtml

More articles from Health and Medicine:

nachricht Diabetes mellitus: A risk factor for early colorectal cancer
27.05.2020 | Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

nachricht Ultra-thin fibres designed to protect nerves after brain surgery
27.05.2020 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Biotechnology: Triggered by light, a novel way to switch on an enzyme

In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".

Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...

Im Focus: New double-contrast technique picks up small tumors on MRI

Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.

researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...

Im Focus: I-call - When microimplants communicate with each other / Innovation driver digitization - "Smart Health“

Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.

When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...

Im Focus: When predictions of theoretical chemists become reality

Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.

Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...

Im Focus: Rolling into the deep

Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.

A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

 
Latest News

Black nitrogen: Bayreuth researchers discover new high-pressure material and solve a puzzle of the periodic table

29.05.2020 | Materials Sciences

Argonne researchers create active material out of microscopic spinning particles

29.05.2020 | Materials Sciences

Smart windows that self-illuminate on rainy days

29.05.2020 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>